A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model

Eye and Contact Lens

Volumn 32, Issue 1, 2006, Pages 46-50

  Donnenfeld, Robert S ^a   Perry, Henry D ^a,c   Solomon, Renée ^a   Jensen, Harold G ^b   Stein, Jonathan ^a   Snyder, Robert W ^d   Wittpenn, John R ^a,e   Donnenfeld, Eric D ^a,c,f  

^a OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^b ALLERGAN INC   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d University of Arizona   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f EAR AND THROAT HOSPITAL   (United States)

Author keywords

Ciprofloxacin; Fluoroquinolone; Gatifloxacin; Keratitis; Laser in situ keratomileusis; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; CORNEA; CORNEA PERFORATION; CORRELATION ANALYSIS; INOCULATION; KERATITIS; KERATOMILEUSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CORNEA; DISEASE MODELS, ANIMAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; FOLLOW-UP STUDIES; KERATITIS; KERATOMILEUSIS, LASER IN SITU; OPHTHALMIC SOLUTIONS; PNEUMOCOCCAL INFECTIONS; RABBITS; STREPTOCOCCUS PNEUMONIAE; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 31944439568     PISSN: 15422321     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icl.0000174761.39015.34     Document Type: Article

References (28)

1. Hyndiuk RA, Eiferman RA, Caldwell DR, et al Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers.Ciprofloxacin Bacterial Keratitis Group. Ophthalmology 1996;103:1854-1862.
2. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991;112(4 suppl):34S-47S.
3. O'Brien TP, Maguire MG, Fink NE, et al Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995;113:1257-1265.
4. Hofmann J, Cetron MS, Farley MM, et al The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-486.
5. Goldstein MH, Kowalski RP, Gordon YJ. The emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review. Ophthalmology 1999;106:1313-1318.
6. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
7. Donnenfeld ED, O'Brien TP, Solomon R, et al Infectious keratitis after photorefractive keratectomy. Ophthalmology 2003;110:743-747.
8. Solomon R, Donnenfeld ED, Azar DT, et al Infectious keratitis after laser in situ keratomileusis: Results of an ASCRS survey. J Cataract Refract Surg 2003;29:2001-2006.
9. Martin M, Turco JH, Zegans ME, et al N Engl Med 2003;348:1112-1121.
10. Mandelbaum S, Forster RK, Gelender H, et al Late onset endophthalmitis associated with filtering blebs. Ophthalmology 1985;92:964-972.
11. Jensen HG, Felix C. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Cornea 1998;17:79-87.
12. Kowalski RP, Dhaliwal DK, Karenchak LM, et al Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.
13. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 2003;121:1229-1233.
14. Upadhyay MP, Karmacharya PC, Koirala S, et al Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol 1991;111:92-99.
15. Ormerod LD. Causation and management of microbial keratitis in subtropical Africa. Ophthalmology 1987;94:1662-1668.
16. Ormerod LD, Hertzmark E, Gomez DS, et al Epidemiology of microbial keratitis in southern California. A multivariate analysis. Ophthalmology 1987;94:1322-1323.
17. Tuberville AW, Wood TO. Corneal ulcers in corneal transplants. Curr Eye Res 1981;1:479-485.
18. Ingraham HJ, Donnenfeld ED, Schrier A, et al Infectious keratitis associated with bullous keratopathy. Presented at the Annual Meeting of the Ocular Microbiology and Immunology Group, Dallas, Texas, 1992.
19. Baum JL. Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on presence of organisms. Surv Ophthalmol Vis Sci 1979;24:97-105.
20. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol Vis Sci 1979;24:105-116.
21. Mather R, Karenchak LM, Romanowski EG, et al Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-466.
22. Huczko E, Conetta B, Bonner D, et al Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998. Int J Antimicrob Agents 2000;16:401-405.
23. Blondeau JM, Zhao X, Hansen G, et al Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433-438.
24. Blondeau JM, Laskowski R, Bjarnason J, et al Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000;14:45-50.
25. de Azavedo JC, Trpeski L, Pong-Porter S, et al In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada. Antimicrob Agents Chemother 1999;43:2299-2301.
26. Fung-Tomc JC, Gradelski E, Valera L, et al Comparative killing rates of fluoroquinolones and cell wall-active agents. Antimicrob Agents Chemother 2000;44:1377-1380.
27. White RL, Enzweiler KA, Friedrich LV, et al Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. Diagn Microbiol Infect Dis 2002;43:207-217.
28. Zhanel GG, Roberts D, Waltky A, et al Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2002;49:807-812.